Did Reckitt Manipulate Gaviscon’s Monopoly After It Came Off Patent? UK

According to information which reached BBC’s Newsnight, Gaviscon, a heartburn drug, continued monopolizing the UK market for much longer than it should have done, and cost the National Health Service (NHS) approximately £40 million extra ($78m) because of this. Internal documents seemed to reveal that executives at Reckitt Benckiser deliberately placed obstacles to prevent generic copies of the drug from being produced and marketed.

More: continued here

Filed under: GastroIntestinal / Gastroentorology on March 15th, 2008